← Back to front page
United States · Platforms & data · MarketBeat

Vertex Pharmaceuticals Prepares for Key Kidney Drug Decision as Pipeline Readouts Loom

Published by MarketBeat · United States 18 min ago
Image from MarketBeat Media, LLC.
Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Vertex Pharmaceuticals (NASDAQ:VRTX) is preparing for a Nov. 30 U.S. regulatory decision on its kidney disease treatment povetacicept, while awaiting clinical results across kidney disease, chronic pain and other conditions, company executives said at a UBS investor event. Susie Lisa, Vertex’s seni

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading